

**LETTER****Metabolism & Endocrinology**

# What is the value of the 60-minute cortisol measurement in the short synacthen test (SST)? Evidence for the defence

Letter to the editor

Adrenocortical insufficiency is caused by failure of the adrenal glands to produce physiological amounts of cortisol and sometimes aldosterone (Addison's Disease). This can be a consequence of pituitary/adrenal failure or suppression of endogenous cortisol production as a result of taking exogenous steroids for a prolonged period of time.

The short synacthen test (SST) is the most commonly performed investigation to assess adrenal function<sup>1,2</sup> as it is more practical than the 'gold standard' insulin tolerance test (ITT).<sup>3</sup> In some centres, a 60-minute serum cortisol post-synacthen is still checked as part of the STT protocol while in other centres it is not deemed necessary to do this.

In the light of these differences in practice, we investigated whether the 60-minute serum cortisol adds value in to interpretation of the SST. All patients attended a single-centre, Salford Royal Foundation Trust (SRFT) for their tests. Data from 207 consecutive SSTs were obtained from the Hospital Electronic Patient Record (EPR). All tests were performed before midday. We looked at a period of 12 months from mid-June 2017 to mid-June 2018. Where a patient had more than 1 SST, the first of the SSTs was analysed.

Serum cortisol was measured by immunoassay on the Siemens Centaur XP analyser (Erlangen, Germany). The analytical range of this assay is 13.8–2069 nmol/L.

Whenever possible, an individual on oral corticosteroids was changed to oral hydrocortisone for 48 hours prior to the SST being performed (if they were not already on this) with omission of hydrocortisone on the evening before and the morning of the test or omission on the morning of the test if on daily prednisolone/dexamethasone. A 30–60-minute cortisol concentration of  $\geq 450$  nmol/L defined a pass; 350–449 nmol/L defined borderline.

Our findings were that in relation to the post-synacthen cortisol pass cut-off of  $\geq 450$  nmol/L, in 16/207 (7.2%) of cases the 60-minute cortisol was  $\geq 450$  nmol/L (adequate adrenocortical function) but the 30-minute cortisol was below this. In all cases where the 30-minute cortisol did indicate a pass (ie, was  $\geq 450$  nmol/L), the 60-minute cortisol was also  $\geq 450$  nmol/L. Thus, the 60-minute cortisol measurement resulted in 7.2% of patients being deemed to have adequate adrenocortical function when the 30-minute cortisol would not have done so.

The 60-minute cortisol therefore retains utility in ruling out adrenocortical insufficiency. Determination of the 60-minute cortisol

is done in some endocrine centres and was reported by Chitale et al<sup>4</sup>. The authors of that paper stated that individuals passing the SST only at 60 minutes tend to exhibit a 'delayed response' to exogenous adrenocorticotrophic hormone (ACTH) but in essence have normally functioning adrenal glands.

As part of this evaluation, we undertook a telephone survey covering all hospitals in the NW of England on 14 April 2021. Of the 23 hospital laboratories surveyed, 11 do not measure both a 30- and a 60-minute cortisol (1 of the 11 laboratories measures a 60-minute but not 30-minute cortisol).

Thus although the evidence base is in support of the value of the 60-minute cortisol,<sup>5–7</sup> this measurement is far from routine at many laboratories. Furthermore, if patient management was to be based solely on the 30-minute sample, they would at least have to undergo further tests or be commenced on unnecessary, long-term steroid replacement therapy. This conclusion was supported in a recent paper by Butt et al<sup>8</sup> who looked at 849 people undergoing SSTs and reported that 9.5% of patients had a suboptimal response at 30 minutes, but reached the threshold value at 60 minutes. There is also the possibility that the 60-minute serum cortisol level may actually be more representative of physiological adrenocortical function than the 30-minute serum cortisol.<sup>9</sup>

To conclude, the 60-minute cortisol retains utility as part of the SST. Reliance on a 60-minute cortisol level can identify all normal and abnormal responses, while relying on 30-minute cortisol level alone may falsely ascribe individuals to having adrenocortical insufficiency. It would surely be sensible to work towards a consensus in relation to inclusion of the 60-minute cortisol in all SST protocols, while taking into account the known variation in cortisol assay performance.

## ROLE OF THE SPONSOR

There was no research sponsor for this study.

## TRANSPARENCY STATEMENT

Dr Heald as corresponding author affirms that this is an honest, accurate and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

## ETHICS STATEMENT

As this project was deemed by our local Research and Development Committee as a quality improvement (QI) project, no individual

patient was contacted in the course of the evaluation and data were fully anonymised prior to analysis, it was not felt that formal ethics permission was required.

## DISSEMINATION OF STUDY RESULTS TO PARTICIPANTS

Dissemination to interested patient groups both locally and nationally will be done once the analysis has been finalised.

## PATIENT CONSENT

This was not deemed necessary as no individual patient was contacted or asked to do anything beyond their usual clinical care.

## ACKNOWLEDGEMENTS

The authors thank Dr Lewis Green (Salford Royal Foundation Trust) for assisting with data collation.

## DISCLOSURE

No author has anything to disclose in relation to conflict of interest.

## AUTHOR CONTRIBUTIONS

AHH and AR conceived the study. MM and LM collected the data. MM, AAF and GY conducted the data analysis. CJD, ML and AAF provided perspective from the laboratory. AN assisted with the literature review. MM, LM, GY, ML, SD, AR, AN, AAF, CJD, AHA, PT and AHH all contributed to writing of the paper. AAF, AHA and PT provided an overview of the manuscript.

## DATA AVAILABILITY STATEMENT

We used patient level data which were fully anonymised prior to analysis. Any requests for access to these data should be made to the corresponding author, Dr Adrian Heald.

Maria Michaelidou<sup>1</sup>  
 Ghasem Yadegarfar<sup>2,3</sup>  
 Lauren Morris<sup>1</sup>  
 Samantha Dolan<sup>1</sup>  
 Adam Robinson<sup>1</sup>  
 Asma Naseem<sup>1</sup>  
 Mark Livingston<sup>4</sup>   
 Christopher J. Duff<sup>5,6</sup>  
 A. H. Aamir<sup>7</sup>  
 Anthony A. Fryer<sup>5,6</sup>   
 Peter Trainer<sup>8</sup>  
 Adrian H. Heald<sup>1,2</sup> 

<sup>1</sup>Department of Endocrinology and Diabetes, Salford Royal Hospital, Salford, UK

<sup>2</sup>The School of Medicine and Manchester Academic Health Sciences Centre, University of Manchester, Manchester, UK

<sup>3</sup>Isfahan University of Medical Sciences, Isfahan, Islamic Republic of Iran

<sup>4</sup>Department of Clinical Biochemistry, Black Country Pathology Services, Walsall Manor Hospital, Walsall, UK

<sup>5</sup>Department of Clinical Biochemistry, University Hospitals of North Midlands NHS Trust, Stoke on Trent, UK

<sup>6</sup>School of Primary, Community and Social Care, Keele University, Keele, UK

<sup>7</sup>Department of Diabetes, Endocrinology and Metabolic Diseases, Hayatabad Medical Complex, Peshawar, Pakistan

<sup>8</sup>Department of Endocrinology, Christie Hospital, Manchester, UK

## Correspondence

Adrian H. Heald, Department of Diabetes and Endocrinology, Salford Royal Hospital, Salford M6 8HD, UK.

Email: adrian.heald@manchester.ac.uk

## ORCID

Mark Livingston  <https://orcid.org/0000-0001-6878-0769>

Anthony A. Fryer  <https://orcid.org/0000-0001-8678-0404>

Adrian H. Heald  <https://orcid.org/0000-0002-9537-4050>

## REFERENCES

- Grossman AB. Clinical review: the diagnosis and management of central hypoadrenalism. *J Clin Endocrinol Metab.* 2010;95:4855-4863.
- Hanna FWF, Issa BG, Keevil B, Fryer AA. Investigating cortisol excess or deficiency: a practical approach. *BMJ.* 2019;367:l6039.
- Jones SL, Trainer PJ, Perry L, Wass JAH, Besser GM, Grossman A. An audit of the insulin tolerance test in adult subjects in an acute investigation unit over one year. *Clin Endocrinol (Oxf).* 1994;41:123-128.
- Chitale A, Musonda P, McGregor AM, Dhataria KK. Determining the utility of the 60 min cortisol measurement in the short synacthen test. *Clin Endocrinol (Oxf).* 2013;79:14-19.
- Dineen R, Mohamed A, Gunness A, et al. Outcomes of the short Synacthen test: what is the role of the 60 min sample in clinical practice? *Postgrad Med J.* 2020;96:67-72.
- Yo WS, Toh LM, Brown SJ, Howe WD, Henley DE, Lim EM. How good is a morning cortisol in predicting an adequate response to intramuscular synacthen stimulation? *Clin Endocrinol (Oxf).* 2014;81:19-24.
- Mansoor S, Islam N, Siddiqui I, Jabbar A. Sixty-minute post-Synacthen serum cortisol level: a reliable and cost-effective screening test for excluding adrenal insufficiency compared to the conventional short Synacthen test. *Singapore Med J.* 2007;48:519-523.
- Butt MI, Alzuhayri N, Amer L, et al. Comparing the utility of 30- and 60-minute cortisol levels after the standard short synacthen test to determine adrenal insufficiency: a retrospective cross-sectional study. *Medicine (Baltimore).* 2020;99:e22621.
- Zueger T, Jordi M, Laimer M, Stettler C. Utility of 30 and 60 minute cortisol samples after high-dose synthetic ACTH-1-24 injection in the diagnosis of adrenal insufficiency. *Swiss Med Wkly.* 2014;144:w13987.